Psilocybin Precision Functional Mapping (data from Psilocybin desynchronizes the human brain)
GeneratedBy : niix2bids==v2.5.0
BIDSVersion : v1.6.0
Psilocybin's acute and persistent effects
Here, we present a randomized cross-over study using precision functional mapping to characterize acute and persistent effects of psilocybin (PSIL) or methylphenidate (MTP) on brain networks. Seven healthy volunteers (mean age 34.1 years, SD=9.8; n=3 females, n=6 Caucasians) underwent 1) extensive baseline imaging, 2) imaging beginning 60-90 minutes after drug exposure, and 3) longitudinal imaging for up to two weeks after drug exposure. Four individuals also participated in an open-label PSIL replication protocol over 6 months later. This dataset includes rsfMRI (using advanced high-resolution multi-echo fMRI), task fMRI, structural, and diffusion basis spectral imaging as well as assessments of subjective experience.
MRI Data Description
-Siemens Prisma scanner
-structural MRI (T1- and T2-weighted images), 0.9 mm isotropic resolution
-resting state fMRI scans (513 frames, 15 minutes each)
-task fMRI scans (233 frames, 6 minutes and 50 seconds each)
Resting state and task scans used an echoplanar imaging sequence with multi-echo (five TEs: 14.20 ms, 38.93 ms, 63.66 ms, 88.39 ms, 113.12 ms), TR 1761 ms, flip angle = 68 degrees, and in-plane acceleration (IPAT/grappa) = 2 [34, 35]. This sequence acquired 72 axial slices (144 mm coverage).
-Nordic Denoising compatible: fMRI scans included 3 noise scans at the end of each run, and mag and phase images are included.
#Participant information
- Total participants, N = 7
- Total participants who completed replication, N=4 (P1, P3, P4, P5)
REST SCANS
P1 P2 P3 P4 P5 P6 P7 P1R P3R P4R P5R
NonDrug 33 36 26 27 28 21 26 11 6 7 7
PSIL 2 2 1 1 4 2 5 4 3 2 3
MTP 2 2 2 3 4 3 3 0 0 0 0
TASK SCANS
NonDrug 12 14 11 5 4 6 12 2 0 2 4
PSIL 2 2 2 2 0 0 2 2 0 2 2
MTP 2 2 2 2 0 2 2 0 0 0 0
ORDER
SubID Drug1 Drug2
P1 MTP PSIL
P2 PSIL MTP
P3 MTP PSIL
P4 MTP PSIL
P5 PSIL MTP
P6 MTP PSIL
P7 PSIL MTP
P1R PSIL
P3R PSIL
P4R PSIL
P5R PSIL
##Notes from MRI sessions
PPFM_session_notes.xlsx
session_data.csv
- Any rest scans that were ended early for any reason (e.g. P6 ses-5 REST3, P4R ses-2 REST3,) will not have the 3 noise images at the end. We copied noise frames from neighboring a rest scan so this did not interfere with NORDIC denoising.
Phenotypic Data Description
PPFM_MEQ_DATA.xlsx
Inclusion/Exclusion Criteria
Please see https://clinicaltrials.gov/study/NCT00088699 for a detailed list, also included below.
#Inclusion Criteria:
-Healthy men and woman between 18 and 45 years of age;
-Have used a psychedelic substance within the previous 5 years but not within the last 6 months;
-No active psychiatric conditions requiring treatment with psychotropic medications (may be included if psychiatric condition is stable and participant is willing to discontinue medication for 1 month prior to participation with permission from their treating provider);
-Able to provide informed consent.
Exclusion Criteria:
-Presence of medical conditions that may confound results of imaging study or that are contraindications to psilocybin exposure (e.g. neurological, renal, hypertension, metabolic or cardiovascular disease or pregnancy);
-No prior exposure to classic psychedelics (psilocybin, LSD, ayahuasca, mescaline);
-Presence of psychiatric conditions that may confound interpretation of results or that are contraindications to psilocybin exposure (e.g. major mood disorder, current substance use disorder, personal or immediate family history (parents, siblings) of any schizophrenia spectrum disorders);
-Use of psychotropic medication during the study;
-Presence of contraindications to MRI scanning (implantable devices, bone hardware, IUD).
-Prior adverse reactions to psychedelics, based on the Challenging Experiences -Questionnaire administered during initial screening
NON_BIDS
NON_BIDS folder contains processed ciftis
https://openneuro.org/datasets/ds006072